Dong-A ST (President/CEO Jae-Hun Jung, KRX:170900) announced on October 18th that its biosimilar IMULDOSA® (active ingredient: ustekinumab, development code DMB-3115), referencing Stelara®, has ...
Some results have been hidden because they may be inaccessible to you